JW Therapeutics: China NMPA accepts JW Therapeutics' sBLA for Carteyva in patients with r/r mantle cell lymphoma
JW Therapeutics, an independent and innovative biotechnology company, announced that the National Medical Products Administration (NMPA) of China accepted the supplemental Biological License Application (sBLA)
Read full article »
JW Therapeutics is a China-based biotechnology company that researches cell-based immunotherapies to treat hematologic malignancies, solid tumors and autoimmune diseases.
Read more